Recent advances in schistosomiasis
- 1 February 2001
- journal article
- research article
- Published by Springer Nature in Current Infectious Disease Reports
- Vol. 3 (1) , 59-67
- https://doi.org/10.1007/s11908-001-0060-1
Abstract
Schistosomiasis is a major parasitic disease, affecting nearly 200 million persons, worldwide. Major advances in our knowledge-in terms of pathogenesis, improved diagnosis, therapeutics (both drugs and strategies), and morbidity assessment-now make schistosomiasis a curable, often preventable disease. In contrast to most other illnesses, most schistosomiasis pathology appears to be reversible over time. For the future, several promising vaccine candidates are already in phase-I or phase-II testing. On the other hand, the range of this disease has been increasing, as water resources are developed in several newly industrialized countries and much of schistosomiasis in sub-Saharan Africa remains largely untreated.Keywords
This publication has 45 references indexed in Scilit:
- Sex‐Dependent Neutralizing Humoral Response toSchistosoma mansoni28GST Antigen in Infected Human PopulationsThe Journal of Infectious Diseases, 2000
- Vaccination of domestic pig with recombinant paramyosinVaccine, 2000
- Paramyosin is a major target of the human IgA response against Schistosoma japonicumParasite Immunology, 1999
- CD4+ T Cell–mediated Granulomatous Pathology in Schistosomiasis Is Downregulated by a B Cell–dependent Mechanism Requiring Fc Receptor SignalingThe Journal of Experimental Medicine, 1998
- Schistosomiasis vaccine development ? the current pictureBioEssays, 1997
- Comparison of the direct faecal smear and two thick smear techniques for the diagnosis of intestinal parasitic infectionsTransactions of the Royal Society of Tropical Medicine and Hygiene, 1996
- SCHISTOSOMIASISGastroenterology Clinics of North America, 1996
- Antischistosomal drugs: Past, present … and future?Pharmacology & Therapeutics, 1995
- Functional and antigenic similarities between a 94-kD protein of Schistosoma mansoni (SCIP-1) and human CD59.The Journal of Experimental Medicine, 1994
- Experimental Models of Immunization Against Schistosomes: Lessons for Vaccine DevelopmentImmunological Investigations, 1992